Lamivudine
China [CN] Lamivudine is a new type of antiviral drug, belonging to nucleoside reverse transcriptase inhibitors. It has a strong inhibitory effect on hepatitis B virus (HBV) in vitro and in experimentally infected animals, and can inhibit the synthesis of HIV virus. This drug is produced by the GlaxoSmithKline Company Group. In the early 1990s, it was used by some countries in Europe and North America to treat AIDS. In the mid-1990s, medical experts discovered that it had an inhibitory effect on the DNA of the hepatitis B virus. In 1998, the US Food and Drug Administration (FDA) was the first to approve it as a treatment for hepatitis B. The State Food and Drug Administration of the Chinese mainland approved the import of this drug mainly for the treatment of hepatitis B. Its Chinese trade name was set as "Hepuding", and it officially began to be sold in the Chinese mainland in 1999. After 10 years of clinical verification, lamivudine is currently the only drug that has been proven to delay the progression of hepatitis and liver cirrhosis, with few side effects and low cost. Currently, 2 million hepatitis B patients across the country are using it.
Click enlarge Image